“Covered” Is Not a Price: What Your Plan Has Actually Promised

Someone at a call centre says your GLP-1 is covered. You still do not know what it costs. "Covered" is a statement about a list — nothing in it commits your plan to a number, a fill date, or even a particular device. Here is the distance between the two, gate by gate.

Gate one: covered means on the formulary

HealthCare.gov defines a formulary as "a list of prescription drugs covered by a prescription drug plan or another insurance plan offering prescription drug benefits. Also called a drug list."¹

That is the entire content of the word. A drug on the list is eligible to be paid for under the rules of your plan. It is not promised at any price, and the list itself can change during the year.

Gate two: prior authorization

HealthCare.gov again, in its own words: prior authorization is "approval from a health plan that may be required before you get a service or fill a prescription in order for the service or prescription to be covered by your plan."²

Note the construction. Until the approval exists, the prescription is not covered — even though the drug is on the covered list. Same word, two different states.

Gate three: covered at what share

A formulary entry does not say what you pay. Three separate mechanisms decide that, and they stack.

Deductible — what you pay in full before the plan begins paying at all.

Coinsurance — a percentage of the cost rather than a flat fee. On a specialty tier this is the one that hurts, because a percentage of an expensive drug is an expensive number.

Copay — a fixed amount per fill.

HealthCare.gov's out-of-pocket-maximum entry lays all three out together and is worth reading once, slowly.³

Gate four: the out-of-pocket maximum, and what it does not catch

For a Marketplace plan in 2026 the out-of-pocket limit "can't be more than $10,600 for an individual and $21,200 for a family."³ Once you reach it, the plan pays 100% of covered benefits for the rest of the plan year.

Read the exclusions, because they are the point. The limit does not include your premiums, out-of-network care, charges above the allowed amount, and — this is the one that matters here — "anything you spend for services your plan doesn't cover."³

So money you spend on a GLP-1 your plan declined does not move you toward the ceiling that would have protected you. Cash spending and covered spending live in separate accounts. We take that apart in cash-pay or insurance: the number that decides it.

Medicare's 2026 arithmetic

Part D was restructured on 1 January 2026. CMS publishes the parameters directly: an annual deductible of $615, then 25% coinsurance during the initial coverage phase, and no enrollee cost sharing at all once annual out-of-pocket spending reaches $2,100.⁴

That $2,100 figure is worth stating precisely, because it is widely misquoted as $2,000. CMS's own fact sheet describes it as "the original 2025 out-of-pocket cap of $2,000, adjusted based on the annual percentage increase in average expenditures for covered Part D drugs."⁴ For 2026 it is $2,100, and plan sponsors may not set it lower.

Covered — but only in one device

The clearest illustration of how narrow "covered" can be is running right now.

Medicare.gov states that from 1 July 2026, under a temporary programme called the Medicare GLP-1 Bridge, Medicare covers Foundayo, Wegovy, and Zepbound — with a parenthesis: "KwikPen only. The program doesn't cover single-dose Zepbound vials or pens."⁵

Same molecule, same manufacturer, same indication. One presentation is covered and the others are not. Medicare.gov gives the beneficiary cost as a $50 monthly copayment.⁵

The clause that makes "covered" ambiguous even when it is true

The Bridge also shows how two coverage routes can cancel each other. CMS's guidance to Part D sponsors is explicit: beneficiaries "who are currently eligible for GLP-1 coverage through the Medicare Part D benefit, regardless of whether it is on the beneficiary's Part D plan's formulary, are not eligible to receive GLP-1 drugs through the Medicare GLP-1 Bridge."⁶

In other words, being coverable under your plan disqualifies you from the cheaper programme — even if your plan's formulary does not actually list the drug. CMS also states that the $245 net price manufacturers accept under the Bridge and the $50 copay sit outside the Part D payment flow, so no part of either counts toward your true out-of-pocket costs.⁶ You can pay $50 a month for eighteen months and be no closer to the $2,100 threshold than you were on day one.

The Bridge is a demonstration running from 1 July 2026 to 31 December 2027, ahead of a wider CMS model called BALANCE, which CMS says is expected to launch in Medicare Part D in January 2027.⁷

The one question that turns "covered" into a number

Do not ask whether a GLP-1 is covered. Ask this instead, in one breath:

"Is it on the formulary, on which tier, does it require prior authorization, what is my cost share on that tier, and have I met my deductible?"

Five facts. Together they produce a price. "Covered" on its own produces nothing — which is exactly why it is the word you get.

For what the other side of that decision costs, see what a GLP-1 membership fee actually buys and how to read a GLP-1 provider's pricing page.